DNAJB13

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, DNAJB13 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated DNAJB13 data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher DNAJB13 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated DNAJB13 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, STAD, and UCEC are the cancer types where DNAJB13 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
HNSCDFSMedianIII,IV0.1220.680.00421view →
STADOSMedianAll0.1000.539.00912view →
UCECDFSMedianAll1.0000.627.01810view →
LIHCOSMedianAll0.1440.688.0139view →
SARCDFSMedianAll0.1210.611.0416view →
PRADDFSMedianAll0.0850.774<.0016view →
CHOLOSMedianAll0.1550.725.0293view →
Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

Exploration